search
Back to results

QT Distance and P Dispersion in ECG in Patients Having Bronchoscopy in the ICU

Primary Purpose

Ventilator-Induced Lung Injury, Pulmonary Atelectasis

Status
Enrolling by invitation
Phase
Not Applicable
Locations
Turkey
Study Type
Interventional
Intervention
Midazolam
Propofol
Sponsored by
Abant Izzet Baysal University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ventilator-Induced Lung Injury

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

* All intubated patients over 18 years of age

Exclusion Criteria:

  • Patients under the age of 18
  • Pregnancy
  • Patients using sedative drugs in the last 24 hours
  • Hypersensitivity to the drugs used in the study
  • Severe cardiac disorder (EF: < 40)
  • Patients using drugs that increase the QT interval (quinidine, lithium, procainamide, amiodarone, sotalol, phenothiazine, tricyclic antidepressants, disopyramide) or reduce the QT interval (digitals)
  • Patients who have hypomagnesemia- hypocalcemia - hypo or hyperthermia - hypo or hypercalcemia - hyperkalemia - hyper or hypothyroidism - myocarditis - mitral heart prolapsus

Sites / Locations

  • Abant izzet baysal university

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Group M

Group P

Arm Description

Bronchoscopy group in which only midazolam will be used

Bronchoscopy group in which midazolam and propofol will be used

Outcomes

Primary Outcome Measures

P wave dispersion (PWD)
PWD in all leads will be measured manually with the X10 magnifying glass. The beginning of the P wave is the point where the isoelectric line and the P wave intersect. The endpoint was taken as the intersection of the isoelectric line and the end point of the P wave.ECG recordings of at least 6 QRS for each lead 1 mV at a rate of 20 mm/s, including the complex 3 channels in amplitude and standard 12 leads will be done simultaneously.
P wave dispersion (PWD)
PWD in all leads will be measured manually with the X10 magnifying glass. The beginning of the P wave is the point where the isoelectric line and the P wave intersect. The endpoint was taken as the intersection of the isoelectric line and the end point of the P wave.ECG recordings of at least 6 QRS for each lead 1 mV at a rate of 20 mm/s, including the complex 3 channels in amplitude and standard 12 leads will be done simultaneously.
P wave dispersion (PWD)
PWD in all leads will be measured manually with the X10 magnifying glass. The beginning of the P wave is the point where the isoelectric line and the P wave intersect. The endpoint was taken as the intersection of the isoelectric line and the end point of the P wave.ECG recordings of at least 6 QRS for each lead 1 mV at a rate of 20 mm/s, including the complex 3 channels in amplitude and standard 12 leads will be done simultaneously.
P wave dispersion (PWD)
PWD in all leads will be measured manually with the X10 magnifying glass. The beginning of the P wave is the point where the isoelectric line and the P wave intersect. The endpoint was taken as the intersection of the isoelectric line and the end point of the P wave.ECG recordings of at least 6 QRS for each lead 1 mV at a rate of 20 mm/s, including the complex 3 channels in amplitude and standard 12 leads will be done simultaneously.
P wave dispersion (PWD)
PWD in all leads will be measured manually with the X10 magnifying glass. The beginning of the P wave is the point where the isoelectric line and the P wave intersect. The endpoint was taken as the intersection of the isoelectric line and the end point of the P wave.ECG recordings of at least 6 QRS for each lead 1 mV at a rate of 20 mm/s, including the complex 3 channels in amplitude and standard 12 leads will be done simultaneously.
QTc (Corrected QT interval) and QTd (QT dispersion) values
The onset of the QRS complex and the descending T wave as the QT interval between the point where the arm cuts the isoelectric TP segment will be taken. QT dispersion (QTd) is the difference between the longest QT and the shortest QT interval. The heart rate-corrected value of the measurement of the QT interval will be used as the QTc. QTc > 500 ms means increased.
QTc (Corrected QT interval) and QTd (QT dispersion) values
The onset of the QRS complex and the descending T wave as the QT interval between the point where the arm cuts the isoelectric TP segment will be taken. QT dispersion (QTd) is the difference between the longest QT and the shortest QT interval. The heart rate-corrected value of the measurement of the QT interval will be used as the QTc. QTc > 500 ms means increased.
QTc (Corrected QT interval) and QTd (QT dispersion) values
The onset of the QRS complex and the descending T wave as the QT interval between the point where the arm cuts the isoelectric TP segment will be taken. QT dispersion (QTd) is the difference between the longest QT and the shortest QT interval. The heart rate-corrected value of the measurement of the QT interval will be used as the QTc. QTc > 500 ms means increased.
QTc (Corrected QT interval) and QTd (QT dispersion) values
The onset of the QRS complex and the descending T wave as the QT interval between the point where the arm cuts the isoelectric TP segment will be taken. QT dispersion (QTd) is the difference between the longest QT and the shortest QT interval. The heart rate-corrected value of the measurement of the QT interval will be used as the QTc. QTc > 500 ms means increased.
QTc (Corrected QT interval) and QTd (QT dispersion) values
The onset of the QRS complex and the descending T wave as the QT interval between the point where the arm cuts the isoelectric TP segment will be taken. QT dispersion (QTd) is the difference between the longest QT and the shortest QT interval. The heart rate-corrected value of the measurement of the QT interval will be used as the QTc. QTc > 500 ms means increased.

Secondary Outcome Measures

Hospitalization
The diagnosis of all patients will be noted on the first day of the ICU.
Bronchoscopy duration
The duration of the procedure will be noted from the beginning of the bronchoscopy till the end of it.
Systolic blood pressure (SBP)
SBP will be measured from the monitor.
Systolic blood pressure (SBP)
SBP will be measured from the monitor.
Systolic blood pressure (SBP)
SBP will be measured from the monitor.
Systolic blood pressure (SBP)
SBP will be measured from the monitor.
Systolic blood pressure (SBP)
SBP will be measured from the monitor.
Diastolic blood pressure (DBP)
DBP will be measured from the monitor.
Diastolic blood pressure (DBP)
DBP will be measured from the monitor.
Diastolic blood pressure (DBP)
DBP will be measured from the monitor.
Diastolic blood pressure (DBP)
DBP will be measured from the monitor.
Diastolic blood pressure (DBP)
DBP will be measured from the monitor.
Mean arterial pressure (MAP)
The MAP is the average of the systolic pressure and the diastolic pressure that is formulized as MAP = (SBP + [2x DBP]) / 3.
Mean arterial pressure (MAP)
The MAP is the average of the systolic pressure and the diastolic pressure that is formulized as MAP = (SBP + [2x DBP]) / 3.
Mean arterial pressure (MAP)
The MAP is the average of the systolic pressure and the diastolic pressure that is formulized as MAP = (SBP + [2x DBP]) / 3.
Mean arterial pressure (MAP)
The MAP is the average of the systolic pressure and the diastolic pressure that formulized as MAP = (SBP + [2x DBP]) / 3.
Mean arterial pressure (MAP)
The MAP is the average of the systolic pressure and the diastolic pressure that is formulized as MAP = (SBP + [2x DBP]) / 3.
Heart rate (HR)
The HR value will be measured from the monitor.
Heart rate (HR)
The HR value will be measured from the monitor.
Heart rate (HR)
The HR value will be measured from the monitor.
Heart rate (HR)
The HR value will be measured from the monitor.
Heart rate (HR)
The HR value will be measured from the monitor.
Central venous pressure (CVP)
The CVP value will be measured from the monitor.
Central venous pressure (CVP)
The CVP value will be measured from the monitor.
Central venous pressure (CVP)
The CVP value will be measured from the monitor.
Central venous pressure (CVP)
The CVP value will be measured from the monitor.
Central venous pressure (CVP)
The CVP value will be measured from the monitor.
Peripheral oxygen saturation
This will be measured from the monitor.
Peripheral oxygen saturation
This will be measured from the monitor.
Peripheral oxygen saturation
This will be measured from the monitor.
Peripheral oxygen saturation
This will be measured from the monitor.
Peripheral oxygen saturation
This will be measured from the monitor.
Airway pressure (P Peak)
This will be measured from the monitor.
Airway pressure (P Peak)
This will be measured from the monitor.
Airway pressure (P Peak)
This will be measured from the monitor.
Airway pressure (P Peak)
This will be measured from the monitor.
Airway pressure (P Peak)
This will be measured from the monitor.
Respiratory rate
This will be measured from the monitor.
Respiratory rate
This will be measured from the monitor.
Respiratory rate
This will be measured from the monitor.
Respiratory rate
This will be measured from the monitor.
Respiratory rate
This will be measured from the monitor.

Full Information

First Posted
June 22, 2022
Last Updated
January 30, 2023
Sponsor
Abant Izzet Baysal University
search

1. Study Identification

Unique Protocol Identification Number
NCT05434624
Brief Title
QT Distance and P Dispersion in ECG in Patients Having Bronchoscopy in the ICU
Official Title
The Effect of Bispectral Index Controlled Sedation on QT Distance and P Dispersion in ECG in Patients Having Bronchoscopy in the Intensive Care Unit
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
June 25, 2022 (Actual)
Primary Completion Date
December 25, 2023 (Anticipated)
Study Completion Date
March 25, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Abant Izzet Baysal University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Fiberoptic bronchoscopy (FOB) is one of the most useful procedures for diagnosing and treating respiratory illnesses to figure out symptoms like hemoptysis, wheezing, or cough. Furthermore, FOB is a frequent method, in intensive care units, for both diagnoses of ventilator-associated pneumonia (VAP) and treatment of atelectasis with bedside sedation.) Propofol is often used in anesthesia for endoscopic treatments. Using propofol for deep anesthesia may be indicated to prevent the patient from feeling discomfort before FOB and to reduce the chance of complications. Although major complications of FOB such as hypoxia and pneumothorax are known, there are limited studies showing its effects on cardiac hemodynamics. The cardiac effects of laryngoscope and intubation were investigated by using different anesthetic agents. In this study, we evaluated the effect of bronchoscopy with BIS-controlled sedation on ECG in ICU patients by monitoring the QT interval and P interval.
Detailed Description
For this study, it was planned to recruit 40 patients who would have FOB in the ICU of Abant İzzet Baysal University Anesthesia department. All intubated patients over 18 years of age who do not meet the exclusion criteria will be included. Before the procedure, all patients were given i.v. 0:02 - 0:04 mg / kg midazolam (zolamide 15 mg / 3 mL, and medications, Turkey) will be administered. Volume-controlled ventilation modes will be preferred during FOB. The pre-trade-inspired FiO2 will be increased to 100%. During the procedure, mean blood pressure, heart rate, oxygen saturation, respiratory rate, CVP, airway pressure, and BIS will be closely monitored. Enteral feeding will be discontinued at least 6 hours before the procedure. At the end of the procedure, the endotracheal tube position will be checked. FOB will be performed using mobile bronchoscopy (Storz FB; 5.0 mm outer diameter). All patients will be monitored with BIS (Bispectral Index A-2000, Aspect Medical Systems, Netherlands) to measure the depth of sedation. Patients will be randomly divided into two groups by an anesthesiologist blinded to the study. Propofol will not be given to Group I after midazolam, while propofol 0.5 mg/kg bolus dose will be administered to Group II. Maintenance will be provided with 60 mcg/kg/min propofol infusion, and the propofol infusion dose will be increased by 10 mcg/kg/min by titration until the BIS value is 40-60 during the procedure. Patients under the age of 18, pregnancy, using sedative drugs in the last 24 hours, hypersensitivity to the drugs used in the study, severe cardiac disorder (EF: < 40), those who increase the QT interval (quinidine, lithium, procainamide, amiodarone, sotalol, phenothiazine, tricyclic Those who use antidepressants, disopyramide) or reducing (digitals) drugs, affecting QT such as hypomagnesemia- hypocalcemia - hypo or hyperthermia - hypo or hypercalcemia - hyperkalemia - hyper or hypothyroidism - myocarditis - mitral heart prolapse, etc. will be excluded from the study. Patients will be randomly divided into 2 equal groups using the closed envelope method. Oral and written consent will be obtained from the first-degree relatives of all patients. All patients will be monitored with BIS to measure the depth of sedation. Age, weight - height, gender, medications used, comorbidities, hospitalization diagnosis, and duration of the procedure will be recorded for both groups. In addition, systolic blood pressure, diastolic blood pressure, mean blood pressure, heart rate, SpO2, BIS, respiratory rate, CVP, and airway pressure will be noted before and after the procedure of the first, fifth, tenth, and fifteenth minute. P wave dispersion, OTc, and OTd values will be calculated according to the max and min wavelengths as the primary outcomes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ventilator-Induced Lung Injury, Pulmonary Atelectasis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
For this study, it was planned to recruit 40 patients who would have FOB in the ICU of Abant İzzet Baysal University Anesthesia. All intubated patients over 18 years of age who do not meet the exclusion criteria will be included. Volume-controlled ventilation modes will be preferred during FOB. The pre-trade-inspired FiO2 will be increased to 100%. During the procedure, mean blood pressure, heart rate, oxygen saturation, respiratory rate, CVP, airway pressure, and BIS will be closely monitored. Enteral feeding will be discontinued at least 6 hours before the procedure. At the end of the procedure, the endotracheal tube position will be checked. FOB will be performed using mobile bronchoscopy (Storz FB; 5.0 mm outer diameter). All patients will be monitored with BIS (Bispectral Index A-2000, Aspect Medical Systems, Netherlands) to measure the depth of sedation.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group M
Arm Type
Experimental
Arm Description
Bronchoscopy group in which only midazolam will be used
Arm Title
Group P
Arm Type
Experimental
Arm Description
Bronchoscopy group in which midazolam and propofol will be used
Intervention Type
Drug
Intervention Name(s)
Midazolam
Other Intervention Name(s)
Zolamid
Intervention Description
Before the procedure, all patients were given i.v. 0:02 - 0:04 mg / kg midazolam (zolamide 15 mg / 3 mL, and medications, Turkey) will be administered.
Intervention Type
Drug
Intervention Name(s)
Propofol
Other Intervention Name(s)
Dormofol
Intervention Description
Propofol 0.5 mg/kg bolus dose will be administered to Group II. Maintenance will be provided with 60 mcg/kg/min propofol infusion, and the propofol infusion dose will be increased by 10 mcg/kg/min by titration until the BIS value is 40-60 during the procedure.
Primary Outcome Measure Information:
Title
P wave dispersion (PWD)
Description
PWD in all leads will be measured manually with the X10 magnifying glass. The beginning of the P wave is the point where the isoelectric line and the P wave intersect. The endpoint was taken as the intersection of the isoelectric line and the end point of the P wave.ECG recordings of at least 6 QRS for each lead 1 mV at a rate of 20 mm/s, including the complex 3 channels in amplitude and standard 12 leads will be done simultaneously.
Time Frame
Before the procedure
Title
P wave dispersion (PWD)
Description
PWD in all leads will be measured manually with the X10 magnifying glass. The beginning of the P wave is the point where the isoelectric line and the P wave intersect. The endpoint was taken as the intersection of the isoelectric line and the end point of the P wave.ECG recordings of at least 6 QRS for each lead 1 mV at a rate of 20 mm/s, including the complex 3 channels in amplitude and standard 12 leads will be done simultaneously.
Time Frame
After the procedure of the first minute
Title
P wave dispersion (PWD)
Description
PWD in all leads will be measured manually with the X10 magnifying glass. The beginning of the P wave is the point where the isoelectric line and the P wave intersect. The endpoint was taken as the intersection of the isoelectric line and the end point of the P wave.ECG recordings of at least 6 QRS for each lead 1 mV at a rate of 20 mm/s, including the complex 3 channels in amplitude and standard 12 leads will be done simultaneously.
Time Frame
After the procedure of the fifth minute
Title
P wave dispersion (PWD)
Description
PWD in all leads will be measured manually with the X10 magnifying glass. The beginning of the P wave is the point where the isoelectric line and the P wave intersect. The endpoint was taken as the intersection of the isoelectric line and the end point of the P wave.ECG recordings of at least 6 QRS for each lead 1 mV at a rate of 20 mm/s, including the complex 3 channels in amplitude and standard 12 leads will be done simultaneously.
Time Frame
After the procedure of the tenth minute
Title
P wave dispersion (PWD)
Description
PWD in all leads will be measured manually with the X10 magnifying glass. The beginning of the P wave is the point where the isoelectric line and the P wave intersect. The endpoint was taken as the intersection of the isoelectric line and the end point of the P wave.ECG recordings of at least 6 QRS for each lead 1 mV at a rate of 20 mm/s, including the complex 3 channels in amplitude and standard 12 leads will be done simultaneously.
Time Frame
After the procedure of the fifteenth minute
Title
QTc (Corrected QT interval) and QTd (QT dispersion) values
Description
The onset of the QRS complex and the descending T wave as the QT interval between the point where the arm cuts the isoelectric TP segment will be taken. QT dispersion (QTd) is the difference between the longest QT and the shortest QT interval. The heart rate-corrected value of the measurement of the QT interval will be used as the QTc. QTc > 500 ms means increased.
Time Frame
Before the procedure
Title
QTc (Corrected QT interval) and QTd (QT dispersion) values
Description
The onset of the QRS complex and the descending T wave as the QT interval between the point where the arm cuts the isoelectric TP segment will be taken. QT dispersion (QTd) is the difference between the longest QT and the shortest QT interval. The heart rate-corrected value of the measurement of the QT interval will be used as the QTc. QTc > 500 ms means increased.
Time Frame
After the procedure of the first minute
Title
QTc (Corrected QT interval) and QTd (QT dispersion) values
Description
The onset of the QRS complex and the descending T wave as the QT interval between the point where the arm cuts the isoelectric TP segment will be taken. QT dispersion (QTd) is the difference between the longest QT and the shortest QT interval. The heart rate-corrected value of the measurement of the QT interval will be used as the QTc. QTc > 500 ms means increased.
Time Frame
After the procedure of the fifth minute
Title
QTc (Corrected QT interval) and QTd (QT dispersion) values
Description
The onset of the QRS complex and the descending T wave as the QT interval between the point where the arm cuts the isoelectric TP segment will be taken. QT dispersion (QTd) is the difference between the longest QT and the shortest QT interval. The heart rate-corrected value of the measurement of the QT interval will be used as the QTc. QTc > 500 ms means increased.
Time Frame
After the procedure of the tenth minute
Title
QTc (Corrected QT interval) and QTd (QT dispersion) values
Description
The onset of the QRS complex and the descending T wave as the QT interval between the point where the arm cuts the isoelectric TP segment will be taken. QT dispersion (QTd) is the difference between the longest QT and the shortest QT interval. The heart rate-corrected value of the measurement of the QT interval will be used as the QTc. QTc > 500 ms means increased.
Time Frame
After the procedure of the fifteenth minute
Secondary Outcome Measure Information:
Title
Hospitalization
Description
The diagnosis of all patients will be noted on the first day of the ICU.
Time Frame
Before the procedure
Title
Bronchoscopy duration
Description
The duration of the procedure will be noted from the beginning of the bronchoscopy till the end of it.
Time Frame
At the end of the procedure
Title
Systolic blood pressure (SBP)
Description
SBP will be measured from the monitor.
Time Frame
Before the procedure
Title
Systolic blood pressure (SBP)
Description
SBP will be measured from the monitor.
Time Frame
After the procedure of the first minute
Title
Systolic blood pressure (SBP)
Description
SBP will be measured from the monitor.
Time Frame
After the procedure of the fifth minute
Title
Systolic blood pressure (SBP)
Description
SBP will be measured from the monitor.
Time Frame
After the procedure of the tenth minute
Title
Systolic blood pressure (SBP)
Description
SBP will be measured from the monitor.
Time Frame
After the procedure of the fifteenth minute
Title
Diastolic blood pressure (DBP)
Description
DBP will be measured from the monitor.
Time Frame
Before the procedure
Title
Diastolic blood pressure (DBP)
Description
DBP will be measured from the monitor.
Time Frame
After the procedure of the first minute
Title
Diastolic blood pressure (DBP)
Description
DBP will be measured from the monitor.
Time Frame
After the procedure of the fifth minute
Title
Diastolic blood pressure (DBP)
Description
DBP will be measured from the monitor.
Time Frame
After the procedure of the tenth minute
Title
Diastolic blood pressure (DBP)
Description
DBP will be measured from the monitor.
Time Frame
After the procedure of the fifteenth minute
Title
Mean arterial pressure (MAP)
Description
The MAP is the average of the systolic pressure and the diastolic pressure that is formulized as MAP = (SBP + [2x DBP]) / 3.
Time Frame
Before the procedure
Title
Mean arterial pressure (MAP)
Description
The MAP is the average of the systolic pressure and the diastolic pressure that is formulized as MAP = (SBP + [2x DBP]) / 3.
Time Frame
After the procedure of the first minute
Title
Mean arterial pressure (MAP)
Description
The MAP is the average of the systolic pressure and the diastolic pressure that is formulized as MAP = (SBP + [2x DBP]) / 3.
Time Frame
After the procedure of the fifth minute
Title
Mean arterial pressure (MAP)
Description
The MAP is the average of the systolic pressure and the diastolic pressure that formulized as MAP = (SBP + [2x DBP]) / 3.
Time Frame
After the procedure of the tenth minute
Title
Mean arterial pressure (MAP)
Description
The MAP is the average of the systolic pressure and the diastolic pressure that is formulized as MAP = (SBP + [2x DBP]) / 3.
Time Frame
After the procedure of the fifteenth minute
Title
Heart rate (HR)
Description
The HR value will be measured from the monitor.
Time Frame
Before the procedure
Title
Heart rate (HR)
Description
The HR value will be measured from the monitor.
Time Frame
After the procedure of the first minute
Title
Heart rate (HR)
Description
The HR value will be measured from the monitor.
Time Frame
After the procedure of the fifth minute
Title
Heart rate (HR)
Description
The HR value will be measured from the monitor.
Time Frame
After the procedure of the tenth minute
Title
Heart rate (HR)
Description
The HR value will be measured from the monitor.
Time Frame
After the procedure of the fifteenth minute
Title
Central venous pressure (CVP)
Description
The CVP value will be measured from the monitor.
Time Frame
Before the procedure
Title
Central venous pressure (CVP)
Description
The CVP value will be measured from the monitor.
Time Frame
After the procedure of the first minute
Title
Central venous pressure (CVP)
Description
The CVP value will be measured from the monitor.
Time Frame
After the procedure of the fifth minute
Title
Central venous pressure (CVP)
Description
The CVP value will be measured from the monitor.
Time Frame
After the procedure of the tenth minute
Title
Central venous pressure (CVP)
Description
The CVP value will be measured from the monitor.
Time Frame
After the procedure of the fifteenth minute
Title
Peripheral oxygen saturation
Description
This will be measured from the monitor.
Time Frame
Before the procedure
Title
Peripheral oxygen saturation
Description
This will be measured from the monitor.
Time Frame
After the procedure of the first minute
Title
Peripheral oxygen saturation
Description
This will be measured from the monitor.
Time Frame
After the procedure of the fifth minute
Title
Peripheral oxygen saturation
Description
This will be measured from the monitor.
Time Frame
After the procedure of the tenth minute
Title
Peripheral oxygen saturation
Description
This will be measured from the monitor.
Time Frame
After the procedure of the fifteenth minute
Title
Airway pressure (P Peak)
Description
This will be measured from the monitor.
Time Frame
Before the procedure
Title
Airway pressure (P Peak)
Description
This will be measured from the monitor.
Time Frame
After the procedure of the first minute
Title
Airway pressure (P Peak)
Description
This will be measured from the monitor.
Time Frame
After the procedure of the fifth minute
Title
Airway pressure (P Peak)
Description
This will be measured from the monitor.
Time Frame
After the procedure of the tenth minute
Title
Airway pressure (P Peak)
Description
This will be measured from the monitor.
Time Frame
After the procedure of the fifteenth minute
Title
Respiratory rate
Description
This will be measured from the monitor.
Time Frame
Before the procedure
Title
Respiratory rate
Description
This will be measured from the monitor.
Time Frame
After the procedure of the first minute
Title
Respiratory rate
Description
This will be measured from the monitor.
Time Frame
After the procedure of the fifth minute
Title
Respiratory rate
Description
This will be measured from the monitor.
Time Frame
After the procedure of the tenth minute
Title
Respiratory rate
Description
This will be measured from the monitor.
Time Frame
After the procedure of the fifteenth minute

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: * All intubated patients over 18 years of age Exclusion Criteria: Patients under the age of 18 Pregnancy Patients using sedative drugs in the last 24 hours Hypersensitivity to the drugs used in the study Severe cardiac disorder (EF: < 40) Patients using drugs that increase the QT interval (quinidine, lithium, procainamide, amiodarone, sotalol, phenothiazine, tricyclic antidepressants, disopyramide) or reduce the QT interval (digitals) Patients who have hypomagnesemia- hypocalcemia - hypo or hyperthermia - hypo or hypercalcemia - hyperkalemia - hyper or hypothyroidism - myocarditis - mitral heart prolapsus
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Emine Ozsari
Organizational Affiliation
Abant İzzet Baysal Üniversitesi University
Official's Role
Study Director
Facility Information:
Facility Name
Abant izzet baysal university
City
Bolu
ZIP/Postal Code
14030
Country
Turkey

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

QT Distance and P Dispersion in ECG in Patients Having Bronchoscopy in the ICU

We'll reach out to this number within 24 hrs